Virtual Therapeutics Buying Akili for $34M

Among the select businesses that aimed to create digital therapeutics—prescription applications that have the FDA’s approval and are protected by insurers—was Akili. The first major accomplishment for Boston-based Akili came when it was granted de novo certification for EndeavorRx, a game designed to help kids with ADHD symptoms.

January 2023 saw the corporation lay off about a third of its workforce. Akili declared in September that it will reorganise the company to shift its emphasis away from prescription drugs. Thanks to pandemic options on some digital health goods, Akili began selling an adult free of prescription version of its ADHD therapy. The company intended to apply for FDA authorization to distribute the two adult and children versions without a need for prescription.

Akili will be purchased by Virtual Therapeutics with an offer in cash of 43 cents per share. The Washington based business creates virtual reality solutions for workplace mental health.